- Summits
- Sponsorship
- Get Tickets
- Retreats
- Media Opportunities
- News
- About
NIPRO CORPORATION has received 510(k) clearance from the US Food and Drug Administration (FDA) for its ELISIO-HX dialyzer, enabling the introduction of its HDs (Hemodialysis powered by super high-flux membrane) approach to the US market.
The FDA clearance, effective July 28, 2026, allows NIPRO to begin commercialising ELISIO-HX in the United States. The technology is designed to support expanded hemodialysis (Expanded HD), an approach that aims to enhance the removal of larger middle molecules while remaining compatible with existing dialysis infrastructure and established clinical workflows.
Hemodialysis remains a cornerstone of treatment for people with end-stage kidney disease in the United States. While conventional high-flux dialysis can remove a broad range of waste products from the blood, there is continued interest in improving the removal of larger middle molecules associated with chronic complications of kidney disease.
NIPRO’s HDs approach combines the ELISIO-HX dialyzer with the company’s proprietary super high-flux membrane technology. The approach is intended to extend the removal profile of larger middle molecules beyond conventional high-flux dialysis while remaining suitable for routine hemodialysis practice.
The FDA clearance marks NIPRO’s entry into the US market with this expanded hemodialysis approach and provides dialysis providers with an additional option for enhancing treatment.
Expanded hemodialysis is an approach to dialysis designed to extend the removal of larger middle molecules compared with conventional high-flux hemodialysis.
These molecules are among the range of uremic toxins that can accumulate in people with kidney failure. Their removal has become an area of interest as researchers and clinicians continue to examine ways of improving dialysis treatment beyond the clearance achieved with conventional approaches. NIPRO’s HDs approach is based on the use of the ELISIO-HX dialyzer and a super high-flux membrane designed to broaden the range of molecules that can be removed during treatment.
At the centre of ELISIO-HX is NIPRO’s proprietary super high-flux membrane technology. The membrane features a precisely controlled pore structure designed to extend the removal profile towards larger middle molecules.
At the same time, the membrane is designed to retain albumin. Albumin is an important blood protein, and maintaining its retention during dialysis is an important consideration when developing technologies aimed at increasing molecule removal.
This membrane design allows NIPRO to target enhanced middle molecule removal while maintaining the established principles of hemodialysis treatment.
One of the key features of NIPRO’s HDs approach is its compatibility with conventional hemodialysis infrastructure. ELISIO-HX is designed to work with existing dialysis systems and established clinical workflows, meaning providers can introduce the technology without investing in new dialysis machines or fundamentally changing how dialysis is delivered.
This integration-focused approach could make it easier for dialysis providers to incorporate expanded hemodialysis into routine care while maintaining existing infrastructure and clinical expertise.
“Innovation creates its greatest value when it becomes accessible in everyday clinical practice,” said Tsuyoshi Yamazaki, President & CEO of NIPRO CORPORATION.
“Our ambition is to broaden the number of patients who can benefit from enhanced hemodialysis. With HDs, enabled by ELISIO-HX and our proprietary super high-flux membrane technology, healthcare professionals can enhance hemodialysis using the infrastructure and expertise they already have.”
Yamazaki added that the FDA clearance represents an important milestone in bringing the approach to patients across the United States.
The introduction of ELISIO-HX to the United States builds on NIPRO’s experience with the technology across Japan, Europe and Latin America.
According to the company, this experience has demonstrated the applicability of HDs across different healthcare settings and provided experience with integrating the approach into routine dialysis care.
“Our experience across multiple regions has shown that HDs can be successfully integrated into routine dialysis care,” said Goichi Miyazumi, President of NIPRO’s Medical Business Global Division.
“Introducing ELISIO-HX in the United States represents another important step in making advanced dialysis technologies available to more patients while supporting healthcare professionals in delivering high-quality care.”
The FDA clearance gives NIPRO the opportunity to introduce ELISIO-HX to one of the world’s largest populations of patients receiving maintenance hemodialysis.
For dialysis providers, the technology offers an additional approach within expanded hemodialysis that is designed to work with conventional dialysis systems and existing models of care.
By combining super high-flux membrane technology with compatibility across conventional hemodialysis infrastructure, NIPRO aims to support broader adoption of expanded hemodialysis without adding new equipment requirements or significant changes to routine clinical workflows.
Stay up to date with the latest developments in medical technology and healthcare at MedTech World Asia 2026 | Hong Kong, taking place from August 26–28. Connect with healthcare leaders, innovators, investors and industry experts exploring the technologies and trends shaping the sector. Explore the agenda and book your slot now.
